Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Dexcom (NASDAQ:DXCM) EVP, Chief HR Officer Sadie Stern (AS:PBHP), sold 1,466 shares of common stock on June 26, 2025, at a price of $85.06, for a total transaction value of $124697. The sale comes as the $34.25 billion medical device company’s stock shows strong momentum, gaining over 9% in the past week. According to InvestingPro analysis, Dexcom maintains a GREAT financial health score, though it currently trades at a premium valuation with a P/E ratio of 64.
Following the transaction, Stern directly owns 108,155 shares of Dexcom, which includes 74,450 unvested restricted stock units. Want deeper insights? InvestingPro offers 12 additional exclusive tips about Dexcom, including detailed analysis of management’s share buyback activities and comprehensive financial health metrics.
The sale was executed under a pre-arranged 10b5-1 trading plan adopted by Stern on February 20, 2025.
In other recent news, DexCom ’s financial outlook has been highlighted by several analysts. Canaccord Genuity increased its price target for DexCom to $106, maintaining a Buy rating, after the company exceeded U.S. revenue expectations in its first-quarter performance. This positive outlook is supported by DexCom’s extensive network of prescribing physicians and anticipated coverage expansion. Goldman Sachs initiated coverage with a Buy rating and a $104 price target, citing untapped consumer adoption potential and strong profit and loss leverage as key growth drivers. Truist Securities also initiated a Buy rating with a $102 target, pointing to DexCom’s leadership in the continuous glucose monitoring market and opportunities for revenue and margin improvements. Piper Sandler maintained its Overweight rating and $100 price target, highlighting DexCom’s expected market share gain among basal insulin patients. RBC Capital Markets reiterated an Outperform rating with a $100 target, noting DexCom’s potential to surpass its 2025 financial guidance and expand U.S. Pharmacy Benefit Manager coverage. These recent developments underscore the confidence among analysts in DexCom’s growth trajectory and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.